Resultado de búsqueda
27 de abr. de 2024 · Novel Cardioprotective Antidiabetic Medications. The thematic series focusses on two groups of antidiabetic medications that have demonstrated cardiovascular benefits with consistently reduced major adverse cardiac events, improvement in heart failure and diminished cardiovascular and all-cause mortality.
24 de abr. de 2024 · In 2021, 19.2–24.1% of the total antidiabetic medication consumption was novel antidiabetics, 39.1–47.2% metformin, 14.8–25.8% sulfonylureas and 23.6–30.5% were insulins. Regional differences in antidiabetic medication consumption were considerable mainly in the case of GLP1As (max/min ratio:3.00), sulfonylureas (2.03) and SGLT2Is (1.92) in 2021.
Hace 2 días · Results 75 739 people initiated second line oral antidiabetic treatment with sulfonylureas (n=25 693, 33.9%), DPP-4 inhibitors ... preference to other drug classes for some people with .
17 de abr. de 2024 · Compared with other antidiabetic drugs, SGLT-2 inhibitor use was associated with a significantly reduced risk for AF (adjusted hazard ratio [HR], 0.77; 95% CI, 0.68-0.88). This finding was more prominent among women (HR, 0.60; 95% CI, 0.45-0.79) compared with men (HR, 0.85; 95% CI, 0.73-0.98; P =.012). The association between reduced ...
Hace 3 días · Type 1 diabetes requires treatment with insulin. The early stages of type 2 diabetes usually can be controlled with noninsulin antidiabetic drugs. However, patients in the later stages of type 2 diabetes often require the addition of insulin to their drug regimen. + + +
Hace 4 días · Read chapter 11 of Basic Concepts in Pharmacology: What You Need to Know for Each Drug Class, 5e online now, exclusively on AccessMedicine. AccessMedicine is a subscription-based resource from McGraw Hill that features trusted medical content from the best minds in medicine.
23 de nov. de 2021 · Anti-obesity drug discovery: advances and challenges. Timo D. Müller, Matthias Blüher, Matthias H. Tschöp & Richard D. DiMarchi. Nature Reviews Drug Discovery 21 , 201–223 ( 2022) Cite this...
